# US 2021/0260046 A1 · Pharmaceutical composition containing ilaprazole or salt thereof and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260046 A1
- Document ID: US20210260046A1
- Status: Published application
- Kind: A1
- Application number: 17/254,830
- Filed: 2018-10-24
- Published: 2021-08-26
- Earliest claimed: 2018-06-22
- Assignees: Livzon Pharmaceutical Group, Inc.
- Applicants: Livzon Pharmaceutical Group Co., Ltd
- Inventors: Tao WANG; Xuemei HOU; Caihua CHENG; Wenqi LU; Xiangsheng KONG; Xiangna ZHANG; Zengqing TU; Yurong ZHANG; Xiaohong WU; Jing LI; Hongdan CHEN; Jialu CHEN
- Web page: https://patentgrep.com/patent/US20210260046A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 47/02: Inorganic compounds
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a pharmaceutical composition containing ilaprazole or a salt thereof, and a preparation method therefor. The pharmaceutical composition contains or consists of ilaprazole or a salt thereof, and a ilaprazole derivative, wherein the amount of the ilaprazole derivative in the pharmaceutical composition is not higher than 1.3 wt % (less than or equal to 1.3 wt %). The composition can be used for treating peptic ulcer bleeding and stress ulcer and preventing upper gastrointestinal hemorrhage caused by severe diseases.

## Claims

### Claim 1

A pharmaceutical composition, comprising or consisting of ilaprazole or a salt thereof and an ilaprazole derivative, wherein the amount of the ilaprazole derivative in the composition is no more than 1.3 wt % 1.3 wt %).

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the amount of the ilaprazole derivative in the composition is no more than 1.2 wt %, preferably no more than 1.1 wt %, more preferably no more than 1.0 wt %, further preferably no more than 0.9 wt %, most preferably no more than 0.8 wt %, such as no more than 0.7 wt %, no more than 0.6 wt %, no more than 0.5 wt %, no more than 0.4 wt %, no more than 0.3 wt %, or no more than 0.2 wt %.

### Claim 3 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the salt of ilaprazole is ilaprazole sodium;
preferably, the purity of the ilaprazole or a salt thereof is no less than 99.9%;
preferably, the ilaprazole derivative is selected from one or more of ilaprazole sulfone, ilaprazole thioether, and ilaprazole ylide;
preferably, the ilaprazole ylide is selected from one or more of ilaprazole carboxyl ylide, ilaprazole hydroxyl ylide, and ilaprazole mercaptomethyl ylide.

### Claim 4 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the amount of the ilaprazole ylide in the composition is no more than 0.9 wt %, preferably no more than 0.8 wt %, more preferably no more than 0.7 wt %, further preferably no more than 0.6 wt %, most preferably no more than 0.5 wt %, such as no more than 0.4 wt %, no more than 0.3 wt %, or no more than 0.2 wt %.

### Claim 5 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the ilaprazole derivative is ilaprazole sulfone, ilaprazole thioether, ilaprazole carboxyl ylide, ilaprazole hydroxyl ylide, and ilaprazole mercaptomethyl ylide;
preferably, the amount of the ilaprazole carboxyl ylide in the composition is no more than 0.3 wt %.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the mass ratio of the ilaprazole sulfone to the ilaprazole thioether is 1:0.5-2, preferably 1:0.5-1 or 1:1-2, more preferably 1:1.

### Claim 7 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the composition comprises or consists of the following parts by weight of substances:
ilaprazole sodium
98.7-99.5 parts;
ilaprazole sulfone
0.1-0.2 parts;
ilaprazole thioether
0.1-0.2 parts;
ilaprazole carboxyl ylide
0.1-0.3 parts;
ilaprazole hydroxyl ylide
0.1-0.3 parts;
ilaprazole mercaptomethyl ylide
0.1-0.3 parts;
preferably, the composition comprises or consists of the following parts by weight of substances:
ilaprazole sodium
98.7 parts;
ilaprazole sulfone
0.2 parts;
ilaprazole thioether
0.2 parts;
ilaprazole carboxyl ylide
0.3 parts;
ilaprazole hydroxyl ylide
0.3 parts;
ilaprazole mercaptomethyl ylide
0.3 parts.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

A powder for injection, comprising the pharmaceutical composition according to claim 1 and a pharmaceutically acceptable carrier;
preferably, the pharmaceutically acceptable carrier is mannitol and EDTA-2Na;
preferably, the weight ratio of mannitol to EDTA-2Na is 10-50:1, preferably 30:1;
preferably, the weight ratio between the weight of the ilaprazole or a salt thereof and the ilaprazole derivative (ie, the pharmaceutical composition according to any one of claims 1 to 6) in total, mannitol, and EDTA-2Na in the powder for injection is 1:3-5:0.1-0.3, preferably 1:3:0.1.

### Claim 9 (depends on 8)

The powder for injection according to claim 8, wherein the pH of the powder for injection is 10.5-11.5, preferably 11.

### Claim 10 (depends on 8)

A method for preparing the powder for injection according to claim 8, comprising the following steps:
(1) weighing the ilaprazole or a salt thereof, the ilaprazole derivative, and the pharmaceutically acceptable carrier according to their prescribed amounts;
(2) dissolving the pharmaceutically acceptable carrier in water for injection, and adjusting the pH of the solution obtained to 10.5-11.5, preferably 10.5 with 2 mol/L sodium hydroxide solution, then adding the prescribed amounts of the ilaprazole or a salt thereof and the ilaprazole derivative to the solution, and after the ilaprazole or a salt thereof and the ilaprazole derivative fully dissolve, adjusting the pH of the solution obtained to 10.5-11.5, preferably 11 with 2 mol/L sodium hydroxide solution, and finally adding water for injection of 4° C. to the solution up to 15000 mg;
(3) sterilizing the solution obtained in step (2) through filtering two times with a filter membrane having a pore size of 0.2 μm and freeze-drying the filtrate obtained to obtain freeze-dried powders for injection, which are then sealed with a stopper in a vacuum pump, removed from the vacuum pump and capped with an aluminum cap.

### Claim 11

A pharmaceutical composition, consisting of ilaprazole sodium and an ilaprazole derivative, wherein the ilaprazole derivative is ilaprazole polysulfide dimer, and/or is selected from one or more of ilaprazole sulfone, ilaprazole thioether and ilaprazole ylide;
preferably, the amount of the ilaprazole derivative is no more than 1.7 wt % (1.7 wt %).

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, wherein the amount of the ilaprazole derivative is no more than 1.6 wt %, preferably no more than 1.5 wt %, more preferably no more than 1.4 wt %, further preferably no more than 1.3 wt %, such as no more than 1.2 wt %, no more than 1.1 wt %, no more than 1.0 wt %, no more than 0.9 wt %, no more than 0.8 wt %, no more than 0.7 wt %, no more than 0.6 wt %, no more than 0.5 wt %, no more than 0.4 wt %, or no more than 0.3 wt %.

### Claim 13 (depends on 11)

The pharmaceutical composition according to claim 11, wherein the purity of the ilaprazole sodium is no less than 99.9%;
preferably, the ilaprazole polysulfide dimer is ilaprazole disulfide dimer and/or ilaprazole trisulfide dimer;
preferably, the ilaprazole ylide is selected from one or more of ilaprazole carboxyl ylide, ilaprazole hydroxyl ylide and ilaprazole mercaptomethyl ylide;
preferably, the ilaprazole derivative is ilaprazole polysulfide dimer, ilaprazole sulfone, ilaprazole thioether, ilaprazole carboxyl ylide, ilaprazole hydroxyl ylide, and ilaprazole mercaptomethyl ylide.

### Claim 14 (depends on 11)

The pharmaceutical composition according to claim 11, wherein the amount of the ilaprazole ylide is no more than 0.9 wt %, preferably no more than 0.8 wt %, more preferably no more than 0.7 wt %, preferably no more than 0.6 wt %, preferably no more than 0.5 wt %, preferably no more than 0.4 wt %, preferably no more than 0.3 wt %, preferably no more than 0.2 wt %;
preferably, the amount of the ilaprazole carboxyl ylide in the composition is no more than 0.3 wt %;
preferably, the mass ratio of the ilaprazole sulfone to the ilaprazole thioether is 1:0.5-2, preferably 1:0.5-1 or 1:1-2, more preferably 1:1;
preferably, the amount of the ilaprazole polysulfide dimer is no more than 0.4 wt %, preferably no more than 0.3 wt %.

### Claim 15 (depends on 11)

The pharmaceutical composition according to claim 11, wherein the ilaprazole polysulfide dimer is ilaprazole disulfide dimer and ilaprazole trisulfide dimer;
preferably, the weight ratio of the ilaprazole disulfide dimer to the ilaprazole trisulfide dimer is 1:0.5-2, preferably 1:0.5-1 or 1:1-2, more preferably 1:1.

### Claim 16 (depends on 11)

The pharmaceutical composition according to claim 11, wherein the pharmaceutical composition comprises or consists of the following parts by weight of substances:
ilaprazole sodium
98.3-99.3 parts;
ilaprazole sulfone
0.1-0.2 parts;
ilaprazole thioether
0.1-0.2 parts;
ilaprazole carboxyl ylide
0.1-0.3 parts;
ilaprazole hydroxyl ylide
0.1-0.3 parts;
ilaprazole mercaptomethyl ylide
0.1-0.3 parts;
ilaprazole disulfide dimer
0.1-0.2 parts;
ilaprazole trisulfide dimer
0.1-0.2 parts;
preferably, the pharmaceutical composition comprises or consists of the following parts by weight of substances:
ilaprazole sodium
98.3 parts;
ilaprazole sulfone
0.2 parts;
ilaprazole thioether
0.2 parts;
ilaprazole carboxyl ylide
0.3 parts;
ilaprazole hydroxyl ylide
0.3 parts;
ilaprazole mercaptomethyl ylide
0.3 parts;
ilaprazole disulfide dimer
0.2 parts;
ilaprazole trisulfide dimer
0.2 parts.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 11)

A powder for injection, comprising the pharmaceutical composition according to claim 11 and a pharmaceutically acceptable carrier;
preferably, the pharmaceutically acceptable carrier is mannitol and EDTA-2Na;
preferably, the weight ratio of mannitol to EDTA-2Na is 10-50:1, preferably 30:1;
preferably, the weight ratio between the weight of the ilaprazole or a salt thereof and the ilaprazole derivative (ie, the pharmaceutical composition according to any one of claims 1 to 6) in total, mannitol, and EDTA-2Na in the powder for injection is 1:3-5:0.1-0.3, preferably 1:3:0.1.

### Claim 18 (depends on 17)

The powder for injection according to claim 17, wherein the pH of the powder for injection is 10.5-11.5, preferably 11.

### Claim 19 (depends on 17)

A method for preparing the powder for injection according to claim 17, comprising the following steps:
(1) weighing the ilaprazole or a salt thereof, the ilaprazole derivative, and the pharmaceutically acceptable carrier according to their prescribed amounts;
(2) dissolving the pharmaceutically acceptable carrier in water for injection, and adjusting the pH of the solution obtained to 10.5-11.5, preferably 10.5 with 2 mol/L sodium hydroxide solution, then adding the prescribed amounts of the ilaprazole or a salt thereof and the ilaprazole derivative to the solution, and after the ilaprazole or a salt thereof and the ilaprazole derivative fully dissolve, adjusting the pH of the solution obtained to 10.5-11.5, preferably 11 with 2 mol/L sodium hydroxide solution, and finally adding water for injection of 4° C. to the solution up to 15000 mg;
(3) sterilizing the solution obtained in step (2) through filtering two times with a filter membrane having a pore size of 0.2 μm and freeze-drying the filtrate obtained to obtain freeze-dried powders for injection which are then sealed with a stopper in a vacuum pump, removed from the vacuum pump and capped with an aluminum cap.

### Claim 20 (depends on 1)

A method for treating digestive tract disease, comprising administering a therapeutically effective amount of the pharmaceutical composition according to claim 1 to a patient in need, wherein, preferably, the digestive tract disease is selected from the group consisting of duodenal ulcers, gastric ulcers and reflux esophagitis.
